Infusystem Holdings, INC 8-K filings

InfuSystem Holdings presents a robust investor update showcasing consistent revenue growth, significant Adjusted EBITDA expansion, and a strategic focus on scaling adjacent therapies and optimizing its platform.

InfuSystem Holdings, Inc. announced its second quarter 2026 financial results, showcasing a 2.6% increase in net revenues to $36.9 million and a 7.6% rise in Adjusted EBITDA to $8.6 million, while reaffirming full-year guidance.

InfuSystem Holdings, Inc. announced it will release its second quarter 2026 financial results on August 4, 2026, and will host an investor conference call.

InfuSystem Holdings, Inc. has approved a $20 million stock repurchase program to run from July 1, 2026, through June 30, 2028, signaling confidence in future growth and financial strength.

InfuSystem Holdings announced the election of Beverly Huss as Chairman of the Board following the 2026 Annual Meeting of Stockholders.

InfuSystem Holdings, Inc. shareholders approved the election of directors and an increase in shares reserved for the 2021 Equity Incentive Plan at the 2026 Annual Meeting.

InfuSystem Holdings, Inc. announced its first quarter 2026 financial results, reporting a 3% decrease in net revenues to $33.7 million but an increase in net income and expanded Adjusted EBITDA margin.

InfuSystem Holdings, Inc. announced it will release its first quarter 2026 financial results on May 7, 2026, and will host an investor conference call the same day.

InfuSystem Holdings, Inc. announced the appointment of Grant Thornton LLP as its new independent registered public accounting firm following a competitive selection process, replacing Deloitte & Touche LLP.

InfuSystem Holdings, Inc. announced its CEO and CFO will participate in the 38th Annual ROTH Conference on March 23, 2026, to host one-on-one investor meetings.

InfuSystem Holdings, Inc. announced record annual revenue of $143.4 million and Adjusted EBITDA of $31.5 million for 2025, driven by growth in both Patient Services and Device Solutions segments.

InfuSystem Holdings, Inc. reported record net revenues, net income, and Adjusted EBITDA for the full year 2025, alongside strategic initiatives aimed at profitable growth and shareholder value.

InfuSystem Holdings, Inc. announced it will release preliminary fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before market open, followed by an investor conference call.

InfuSystem Holdings, Inc. announced that two of its electronic infusion pumps used in pain management will receive separate payment under the NOPAIN Act, effective January 1, 2026.

InfuSystem Holdings, Inc. highlights six consecutive years of record revenue, strong cash flow, and strategic expansion into new therapies in its latest investor presentation.

InfuSystem Holdings, Inc. announced its CEO and CFO will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, to host one-on-one investor meetings.

InfuSystem Holdings, Inc. announced record net revenues of $36.5 million for Q3 2025, a 3% increase year-over-year, alongside a 25% rise in net income and reaffirmed its full-year 2025 guidance.

InfuSystem Holdings, Inc. announced it will release its third quarter 2025 financial results and host a conference call on November 4, 2025.

InfuSystem Holdings, Inc. highlights six consecutive years of record revenue, strategic partnerships, and strong financial performance in its latest investor presentation.

InfuSystem Holdings, Inc. announced its CEO and CFO will present at the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, and host one-on-one meetings.

InfuSystem Holdings, Inc. announced record second quarter 2025 financial results, featuring significant revenue growth, substantial increases in net income and Adjusted EBITDA, and a strategic focus on margin expansion.

InfuSystem Holdings, Inc. announced it will release its second quarter 2025 financial results and host a conference call on August 5, 2025.

InfuSystem Holdings, Inc. has amended its credit agreement, extending the maturity date to July 15, 2030, and substantially increasing its aggregate permitted acquisition capacity to $580 million.

InfuSystem Holdings, Inc. has finalized a new employment agreement for its President and CEO, Carrie Lachance, detailing her compensation and equity incentives, while also amending its corporate charter to streamline governance and establish exclusive legal forums.

InfuSystem Holdings' stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the share reserve to 6,000,000 shares, and elected directors at the 2025 Annual Meeting.

InfuSystem Holdings, Inc. releases an investor presentation on May 9, 2025, outlining its growth strategy and financial performance.

InfuSystem Holdings announces record net revenues of $34.7 million for Q1 2025, representing a 9% increase year-over-year, alongside a significant 64% rise in Adjusted EBITDA.

InfuSystem Holdings, Inc. will release its first quarter 2025 financial results on May 8, 2025, before the market opens and host a conference call at 9:00 a.m. Eastern Time to discuss the results.

InfuSystem Holdings, Inc. announces that Richard DiIorio will step down as CEO, with Carrie Lachance appointed as the new CEO, effective May 19, 2025, while reaffirming its full-year 2025 guidance.

InfuSystem Holdings announces record net revenues of $134.9 million and a 13% increase in Adjusted EBITDA for the full year 2024, driven by growth in both Patient Services and Device Solutions segments.